Skip to main content

10X Genomics, Inc. (TXG)

NASDAQ: TXG · IEX Real-Time Price · USD
148.85
-2.14 (-1.42%)
At close: Nov 26, 2021 1:00 PM
150.50
1.65 (1.11%)
After-hours:Nov 26, 2021 3:47 PM EST
Market Cap16.63B
Revenue (ttm)459.18M
Net Income (ttm)-455.35M
Shares Out111.71M
EPS (ttm)-4.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume645,903
Open160.80
Previous Close150.99
Day's Range148.44 - 154.07
52-Week Range128.15 - 208.99
Beta1.40
AnalystsBuy
Price Target192.38 (+29.2%)
Earnings DateNov 3, 2021

About TXG

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for me...

IndustryLife Sciences Tools & Services
IPO DateSep 12, 2019
CEOSerge Saxonov
Employees1,148
Stock ExchangeNASDAQ
Ticker SymbolTXG
Full Company Profile

Financial Performance

In 2020, 10X Genomics's revenue was $298.85 million, an increase of 21.53% compared to the previous year's $245.89 million. Losses were -$542.73 million, 1,636.7% more than in 2019.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for 10X Genomics stock is "Buy." The 12-month stock price forecast is 192.38, which is an increase of 29.24% from the latest price.

Price Target
$192.38
(29.24% upside)
Analyst Consensus: Buy

News

10x Genomics Stock: Bull vs. Bear

After a hot start, the stock has recently lagged the market. Is now a good time to buy?

2 days ago - The Motley Fool

Better Buy: 10x Genomics vs. DermTech

Both companies offer disruptive new solutions in their niches of the healthcare space.

Other symbols:DMTK
2 weeks ago - The Motley Fool

10x Genomics Clocks 74% Jump In Q3 Revenues; Raises Top End Of Sales Guidance

10x Genomics Inc (NASDAQ: TXG) reported Q3 sales of $125.3 million, beating the consensus of $122.62 million. Sales increased 74% Y/Y, primarily due to increased consumables revenue driven by growth in ...

3 weeks ago - Benzinga

10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of 16.67% and 0.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

10x Genomics Reports Third Quarter 2021 Financial Results

PLEASANTON, Calif., Nov. 3, 2021 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2021.

3 weeks ago - PRNewsWire

10x Genomics Earnings Preview

10x Genomics (NASDAQ:TXG) is set to give its latest quarterly earnings report on Wednesday, 2021-11-03. Here's what investors need to know before the announcement.

3 weeks ago - Benzinga

10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 weeks ago - Zacks Investment Research

10x Genomics Celebrates Opening of Singapore Manufacturing and Commercial Hub

SINGAPORE, Oct. 25, 2021 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today marked a major Asia Pacific (APAC) expansion with ...

1 month ago - PRNewsWire

Wall Street Analysts See a 27% Upside in 10x Genomics (TXG): Can the Stock Really Move This High?

The mean of analysts' price targets for 10x Genomics (TXG) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys...

1 month ago - Zacks Investment Research

3 COVID Stocks That Can Turn $1,000 Into $10,000

Our trio of contributors offer three COVID-19 stocks that will zoom higher, even as we emerge from the pandemic.

Other symbols:AVIRDOCS
1 month ago - The Motley Fool

10x Genomics to Report Third Quarter Financial Results on November 3, 2021

PLEASANTON, Calif., Oct. 7, 2021 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3rd, 2021.

1 month ago - PRNewsWire

Buy 3 Medical Info Systems Stocks to Brave Industry-wide Challenges

Stocks like 10x Genomics Inc. (TXG), Omnicell, Inc. (OMCL) and Inspire Medical Systems, Inc. (INSP) are expected to gain despite pandemic-led disruptions.

Other symbols:INSPOMCL
1 month ago - Zacks Investment Research

Here's Why 10x Genomics (TXG) is Poised for a Turnaround After Losing 22.3% in 4 Weeks

10x Genomics (TXG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising...

1 month ago - Zacks Investment Research

Why 10x Genomics Shares Are Trading Lower Today

10x Genomics (NASDAQ:TXG) shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral and announced a $180 price target. 10x Genomics' stock is currently down 7.53% to a pr...

2 months ago - Benzinga

10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

PLEASANTON, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference.

2 months ago - GlobeNewsWire

10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit

PLEASANTON, Calif., Aug. 06, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit.

3 months ago - GlobeNewsWire

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of 61.54% and 2.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Will 10x Genomics (TXG) Report Negative Earnings Next Week? What You Should Know

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad

Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes

4 months ago - GlobeNewsWire

Top 5 Trades of the Eaton Vance Worldwide Health Sciences Fund

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the second quarter of the year this week.

Other symbols:ABTAGTIDHRHAEHUMINOV
4 months ago - GuruFocus

10x Genomics to Report Second Quarter Financial Results on August 4, 2021

PLEASANTON, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the second quarter 2021 after market close on Wednesday, August 4th,...

4 months ago - GlobeNewsWire

These 3 Cathie Wood Stocks Are Still Going Strong

Even with some setbacks in 2021, the ARK Invest manager has still found some winners.

Other symbols:SESHOP
5 months ago - The Motley Fool

High-Growth Stocks Come Back Into Investors' Favor

The short-term bottom for next-generation enterprises is in, and high multiple stocks are returning to investors' favor.

5 months ago - Zacks Investment Research

Here's Why 10x Genomics Can't Satisfy Short-Term Investors

Long-term investors should keep perspective.

5 months ago - The Motley Fool

Strength Seen in 10x Genomics (TXG): Can Its 3.9% Jump Turn into More Strength?

10x Genomics (TXG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

5 months ago - Zacks Investment Research